- Home
- REAL vs ZURA Comparison
REAL vs ZURA Comparison
Compare REAL & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- ZURA
- Stock Information
- Founded
- REAL 2011
- ZURA 2022
- Country
- REAL United States
- ZURA United States
- Employees
- REAL N/A
- ZURA N/A
- Industry
- REAL Other Specialty Stores
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REAL Consumer Discretionary
- ZURA Health Care
- Exchange
- REAL Nasdaq
- ZURA Nasdaq
- Market Cap
- REAL 641.9M
- ZURA 69.9M
- IPO Year
- REAL 2019
- ZURA N/A
- Fundamental
- Price
- REAL $5.31
- ZURA $1.18
- Analyst Decision
- REAL Buy
- ZURA Buy
- Analyst Count
- REAL 5
- ZURA 7
- Target Price
- REAL $8.40
- ZURA $14.33
- AVG Volume (30 Days)
- REAL 3.0M
- ZURA 709.5K
- Earning Date
- REAL 08-05-2025
- ZURA 08-08-2025
- Dividend Yield
- REAL N/A
- ZURA N/A
- EPS Growth
- REAL N/A
- ZURA N/A
- EPS
- REAL N/A
- ZURA N/A
- Revenue
- REAL $616,717,000.00
- ZURA N/A
- Revenue This Year
- REAL $11.70
- ZURA N/A
- Revenue Next Year
- REAL $10.10
- ZURA N/A
- P/E Ratio
- REAL N/A
- ZURA N/A
- Revenue Growth
- REAL 11.89
- ZURA N/A
- 52 Week Low
- REAL $2.24
- ZURA $0.97
- 52 Week High
- REAL $11.38
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- REAL 52.98
- ZURA 48.73
- Support Level
- REAL $4.71
- ZURA $1.00
- Resistance Level
- REAL $5.30
- ZURA $1.22
- Average True Range (ATR)
- REAL 0.26
- ZURA 0.08
- MACD
- REAL 0.04
- ZURA -0.00
- Stochastic Oscillator
- REAL 100.00
- ZURA 52.00
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.